![Louis F. Fries](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Louis F.
Fries held several positions in the clinical development and affairs field, including Director of Clinical Development at Nabi Biopharmaceuticals and Univax Biologics, Inc. He also served as Vice President of Clinical Affairs at ID Biomedical Corp.
from 2005 to 2011 and as Chief Medical Officer and Vice President at Novavax, Inc. from 2014 to 2016.
Fries holds a doctorate degree from Duke University and an undergraduate degree from The Johns Hopkins University.
Anciens postes connus de Louis F. Fries
Sociétés | Poste | Fin |
---|---|---|
ID Biomedical Corp.
![]() ID Biomedical Corp. Medical SpecialtiesHealth Technology ID Biomedical Corp. develops gene-based disease testing and subunit vaccines. It conducts research, development, manufacturing, sales, and marketing from its facilities in Canada and in the United States. The company was founded in 1991 and is headquartered in Vancouver, Canada. | Directeur Technique/Scientifique/R&D | 01/01/2011 |
Nabi Biopharmaceuticals
![]() Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Directeur Technique/Scientifique/R&D | - |
Univax Biologics, Inc.
![]() Univax Biologics, Inc. BiotechnologyHealth Technology Univax Biologics, Inc. developed and manufactured anti-infective products. The firm developed different products that prevented and treated infectious diseases and related complications through activation targeting of human immune system. Its products included vaccines for long-term protection, specific polyclonal antibodies for short-term protection and therapeutic intervention. The company was founded in 1988 and was located in Rockville, MD. | Directeur Technique/Scientifique/R&D | - |
NOVAVAX, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Louis F. Fries
Duke University | Doctorate Degree |
The Johns Hopkins University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
NOVAVAX, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
ID Biomedical Corp.
![]() ID Biomedical Corp. Medical SpecialtiesHealth Technology ID Biomedical Corp. develops gene-based disease testing and subunit vaccines. It conducts research, development, manufacturing, sales, and marketing from its facilities in Canada and in the United States. The company was founded in 1991 and is headquartered in Vancouver, Canada. | Health Technology |
Nabi Biopharmaceuticals
![]() Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Health Technology |
Univax Biologics, Inc.
![]() Univax Biologics, Inc. BiotechnologyHealth Technology Univax Biologics, Inc. developed and manufactured anti-infective products. The firm developed different products that prevented and treated infectious diseases and related complications through activation targeting of human immune system. Its products included vaccines for long-term protection, specific polyclonal antibodies for short-term protection and therapeutic intervention. The company was founded in 1988 and was located in Rockville, MD. | Health Technology |